Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Zimberelimab |
Synonyms | |
Therapy Description |
Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Zimberelimab | GLS-010|AB122|AB-122|GLS010 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03846310 | Phase I | Carboplatin + Etrumadenant + Pemetrexed Disodium Zimberelimab Carboplatin + Etrumadenant + Pembrolizumab + Pemetrexed Disodium | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | Completed | USA | 3 |
NCT04087018 | Phase I | Zimberelimab | Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT04736173 | Phase III | Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab | Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10) | Active, not recruiting | USA | TUR | GRC | 9 |
NCT04262856 | Phase II | AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) | Active, not recruiting | USA | CAN | AUS | 4 |
NCT06431633 | Phase II | Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN) | Not yet recruiting | ESP | 0 |
NCT04656535 | Phase I | Zimberelimab AB154 AB154 + Zimberelimab | AB154 Combined With AB122 for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT06048484 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pegfilgrastim AB680 + Etrumadenant + Zimberelimab AB680 + Zimberelimab Zimberelimab | Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc) | Recruiting | USA | 0 |
NCT06238921 | Phase Ib/II | Sacituzumab govitecan-hziy + Zimberelimab Zimberelimab | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | Recruiting | USA | 0 |